Why Enochian’s “Crina” app wants to make clinical data less painful

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 17:03. Details in the imprint.

With the **Crina** mobile app, Enochian Biosciences takes an unexpectedly practical turn - away from pure lab work and into the daily grind of clinical trial paperwork that usually lives in crumpled paper diaries and half-filled spreadsheets.

What Crina tries to fix

Clinical trials still depend heavily on paper diaries and fragmented Excel lists, which means lost notes, illegible handwriting, and data entered days after events actually happened. Crina wants to pull that mess into one tidy, always-with-you app.

In concrete terms, Crina is designed as a digital patient diary and documentation hub that lets participants log symptoms, medication times, and side effects directly on their phone while investigators see structured data on their dashboards in near real time.

Design built around the patient

On screen, Crina keeps things deliberately calm - large buttons, clear fonts, and plain language instead of clinical jargon that scares off non-specialists who just want to tap, swipe, and get back to their day.

Reminders nudge users with gentle notifications rather than aggressive alarms, so the app feels more like a helpful assistant than a clinical monitor that constantly shouts at you for missing a dose or forgetting a diary entry.

Why trials might like it too

For study teams, a tool like Crina promises cleaner data with fewer gaps, because entries are time stamped at the moment of logging instead of reconstructed from memory at the next site visit days later.

The structured data export means less manual transcription from paper into electronic case report forms, which cuts both errors and overtime for already stretched coordinators who usually juggle binders, email, and spreadsheets at once.

Limits and open questions

There are, however, obvious constraints - any app handling clinical data has to satisfy strict privacy rules, integrate cleanly into existing systems, and stay usable even for older participants or those with limited digital experience.

Crina will also live or die by how reliably it works in patchy network situations and whether Enochian can keep development and support running long term, despite the company’s modest size and focus on high-risk biotech projects.

Where Enochian stands

Enochian Biosciences remains first and foremost a small biotech player focused on cell and gene therapy concepts, with Crina sitting to the side as a digital support tool rather than the core value driver of the business.

Shares of Enochian Biosciences (US29359T1097) trade on Nasdaq in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.